Shares of Verrica Pharmaceuticals Inc. (VRCA) have gained nearly 30% year-to-date as this dermatology therapeutics company looks forward to the PDUFA date of its lead product candidate YCANTH, which is slated for June 23, 2021.
YCANTH, also known as VP-102, is a proprietary drug-device combination of Cantharidin administered through the company's single-use precision applicator. YCANTH is proposed for the treatment of molluscum contagiosum, a highly contagious viral skin disease that affects approximately six million people - primarily children - in the United States.
For comments and feedback contact: editorial@rttnews.com
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.